Pierre Fabre Laboratories

Colon cancer
#Colorectal cancer #European Commission #Pierre Fabre Laboratories

EC approves metastatic colorectal cancer combination regimen 

The European Commission (EC) has approved a combination therapy for the treatment of metastatic colorectal cancer.  Braftovi (encorafenib) has been approved in combination with cetuximab and FOLOX for the first-time treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC).  The approval is based on the results from the Phase III BREAKWATER trial, which… Read More

#News #Regulatory

T cells
#Advanced Therapies #Atara #Cell and gene therapy #Cell therapy #FDA #Pierre Fabre Laboratories

FDA rejects second application for off-the-shelf T-cell therapy

The US Food and Drug Administration (FDA) said it is unable to approve the Atara Biotherapeutics’ off-the-shelf" allogeneic T-cell immunotherapy Ebvallo (tabelecleucel) based on the company’s Biologics License Application (BLA).  The regulator ruled that the single arm ALLELE trial, which Atara’s says was previously confirmed by the FDA as adequate… Read More

#News #Regulatory

Colon cancer
#China #Colorectal cancer #Monoclonal antibodies #Oncology #Pierre Fabre Laboratories

China approval for colorectal cancer combination treatment

The Chinese authorities have granted a marketing authorisation for Pierre Fabre Laboratories’ Braftovi, in combination with cetuximab, for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer, after prior systemic therapy.  The approval is based on the Phase III BEACON CRC trial, which demonstrated a significant improvement in overall… Read More

#News #Regulatory

Monoclonal antibodies
#Antibodies #Biotechnology #Collaboration #Drug development #Drug discovery #Pierre Fabre Laboratories #RedRidge

Pharma/biotech biparatopic antibody collaboration agreed

Pierre Fabre Laboratories and RedRidge have announced an exclusive R&D collaboration and license agreement to identify and develop biparatopic antibody (BPA) drug candidates against multiple targets. In line with Pierre Fabre Laboratories’ innovation strategy, the partnership’s therapeutic focus will be on precision oncology as well as dermatology and rare diseases. Read More

#News